Gamida Cell Ltd

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions. To access the conference call by phone, plea.

Gamida Cell to Report Second Quarter 2023 Financial Results

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the publication in press of a prospective sub-study of the Phase 3 clinical trial for Omisirge® (omidubicel-onlv), the company's allogeneic stem cell transplant therapy, characterizing immune reconstitution kinetics following hematopoietic stem cell transplantation (HCT) with Omisirge compared to umbilical cord blood (UCB). The article appears online.

Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell's Omisirge® (omidubicel-onlv)

Veteran Oncology Researcher to Guide Investment in Breakthrough Cancer Treatments LOS ANGELES , July 10, 2023 /PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced that Julian Adams, Ph.D., a longtime oncology researcher and retired pharmaceutical industry chief executive, was named the organization's first Chief Science Officer.

STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER

Gamida Cell (GMDA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Gamida Cell (GMDA) Looks Ripe for Bottom Fishing

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, will host an Investor Day on Thursday, June 29, 2023 beginning at 8 a.m. EDT in New York City, and will also be available via a live webcast. The Investor Day will feature presentations by two thought leaders in stem cell transplant: Steven M. Devine, M.D., Chief Medical Officer at the National Marrow Donor Program® (NMDP)/Be The Match®, who will discuss the unmet n.

Gamida Cell To Host Investor Day

Gamida Cell Ltd. (GMDA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.

Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden Cross

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET. Ms. Korfin's presentation will include an overview of the company's corporate strategy and commercial strategy for Omisirge®. The webcast will be available on the “Invest.

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cell's investigational natural killer (NK) cell therapy candidate GDA-201 will be shared at the International Society for Cell and Gene Therapy (ISCT) 2023 Annual Meeting. The meeting takes place May 31-June 3 in Paris, France. Additionally, a poster will be presented with data from Gamida Cell's pre-clin.

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately. Shai Lankry, who has served as the company's CFO for the past five years, is stepping down as CFO today and will leave the company June 2. The transition is part of a planned leadership change first shared with the investor community in August 2022 and designed to coinc.

Gamida Cell Appoints Terry Coelho as CFO

Gamida Cell Ltd. (NASDAQ:GMDA ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Scientific Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Gil Blum - Needham & Company Vernon Bernardino - H.C.

Gamida Cell Ltd. (GMDA) Q1 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended March 31, 2023. Gamida Cell recently announced that the U.S. Food and Drug Administration (FDA) has approved Omisirge® (omidubicel-onlv) for patients with hematologic malignancies who are planned for allogeneic hematopoietic stem cell transplantation. Please see full Prescribing In.

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conferenc.

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

Gamida Cell (NASDAQ: GMDA ) stock is falling on Wednesday after the cell therapy company revealed details of a public securities offering. According to a press release from the company, it is selling both shares of GMDA stock, as well as warrants to purchase shares of its stock.

Why Is Gamida Cell (GMDA) Stock Down 19% Today?

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share and accompanying warrant, for gross proceeds of approximately $22.

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares.

Gamida Cell Announces Launch of Public Offering of Securities

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.

Gamida Cell Stock Jumps Over 100% on FDA Approval

Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidate Omisirge received breakthrough therapy designation, priority review and orphan drug designation from the FDA, sending shares of the Boston-based company nearly 45% higher in midday trading.

Gamida Cell shares jump on FDA recognition of allogeneic cell therapy

Gamida Cell (NASDAQ: GMDA ) stock is taking off on Tuesday after getting an update from the FDA concerning Omisirge. Omisirge is the company's cell therapy designed to treat patients with hematologic malignancies planned for umbilical cord blood transplantation after myeloablative conditioning.

Why Is Gamida Cell (GMDA) Stock Up 48% Today?

SAB Biotherapeutics

vTv Therapeutics

For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.

Promising Upsides on these Biotech Penny Stocks

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S.

Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

FiscalNote Holdings Inc

Praxis Precision Medicines

Penny stocks to watch this week. The post 3 Hot Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks To Watch In The Stock Market Today

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022. Net loss for 2022 was $79.4 million, compared to a net loss of $89.8 million in 2021. As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million.

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately. “On behalf of my fellow board members and Gamida Cell's employees, I want to thank Robert for his dedicated service to this company,” said Abbey Jenkins, Gamida Cell President and Chief Executive Officer.

Gamida Cell Announces Changes to Board of Directors

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call.

News for Gamida Cell Ltd Stock (GMDA)